Q-omics provides the consensus-scored MTCO3P39 profile across patient tissues and cancer cell-line models. MTCO3P39 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MTCO3P39 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, MTCO3P39 RNA expression shows 4,893 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, LIHC, and STAD as cancer lineages where MTCO3P39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO3P39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO3P39 survival associations across molecular data types. MTCO3P39 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO3P39 RNA expression–survival associations across cancer types. High MTCO3P39 expression shows unfavorable associations in KIRC, ACC, LUSC and ESCA, but favorable associations in LUAD and READ. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for MTCO3P39 RNA expression.
This table summarizes MTCO3P39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO3P39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO3P39 shows higher tumor expression in LIHC. The LIHC box plot shows higher MTCO3P39 RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .014).
This table shows molecular features associated with MTCO3P39 in patient tissues and cancer cell lines. In patient samples, MTCO3P39 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
